rAAV Vector Product Characterization and Stability Studies

Methods in Molecular Biology

Volumn 807, Issue , 2011, Pages 405-428

  Snyder, Richard O ^a,c   Audit, Muriel ^b   Francis, Joyce D ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b GenoSafe SAS   (France)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adeno associated virus; Assay; Gene therapy; Quality assurance; Quality control; Testing

Indexed keywords

ADENO ASSOCIATED VIRUS; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; QUALITY CONTROL; REVIEW;

ANIMALS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; QUALITY CONTROL;

EID: 83455225585     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-370-7_17     Document Type: Chapter

References (37)

1. Wagner, J. A., Messner, A. H., Moran, M. L., Daifuku, R., Kouyama, K., Desch, J. K., Manley, S., Norbash, A. M., Conrad, C. K., Friborg, S., Reynolds, T., Guggino, W. B., Moss, R. B., Carter, B. J., Wine, J. J., Flotte, T. R., and Gardner, P. (1999) Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus, Laryngoscope 109, 266–274.
2. Flotte, T. R., Zeitlin, P. L., Reynolds, T. C., Heald, A. E., Pedersen, P., Beck, S., Conrad, C. K., Brass-Ernst, L., Humphries, M., Sullivan, K., Wetzel, R., Taylor, G., Carter, B. J., and Guggino, W. B. (2003) Phase I trial of intrana-sal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study, Hum Gene Ther 14, 1079–1088.
3. Stedman, H., Wilson, J. M., Finke, R., Kleckner, A. L., and Mendell, J. (2000) Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors, Hum Gene Ther 11, 777–790.
4. Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., Couto, L. B., Leonard, D. G., Johnson, F. A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A. W., Kay, M. A., High, K. A., and Glader, B. (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B, Blood 101, 2963–2972.
5. Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D. J., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G., Sharrar, W., Liouterman, L., Camp, A., Kolodny, E., Samulski, J., and Leone, P. (2002) Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain, Hum Gene Ther 13, 1391–1412.
6. During, M. J., Kaplitt, M. G., Stern, M. B., and Eidelberg, D. (2001) Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation, Hum Gene Ther 12, 1589–1591.
7. Flotte, T. R., Brantly, M. L., Spencer, L. T., Byrne, B. J., Spencer, C. T., Baker, D. J., and Humphries, M. (2004) Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults, Hum Gene Ther 15, 93–128.
8. Crystal, R. G., Sondhi, D., Hackett, N. R., Kaminsky, S. M., Worgall, S., Stieg, P., Souweidane, M., Hosain, S., Heier, L., Ballon, D., Dinner, M., Wisniewski, K., Kaplitt, M., Greenwald, B. M., Howell, J. D., Strybing, K., Dyke, J., and Voss, H. (2004) Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis, Hum Gene Ther 15, 1131–1154.
9. Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., Spencer, C., Byrne, B. J., Wilson, J. M., and Flotte, T. R. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy, Proc Natl Acad Sci U S A 106, 16363–16368.
10. Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, A., Leonard, D., Wright, J. F., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H. C., High, K. A., and Kay, M. A. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med 12, 342–347.
11. High, K. A. (2007) Update on progress and hurdles in novel genetic therapies for hemophilia, Hematology Am Soc Hematol Educ Program, 466–472.
12. Ponder, K. P. (2011) Hemophilia gene therapy: a holy grail found, Mol Ther 19, 427–428.
13. Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., and High, K. A. (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells, Blood 114, 2077–2086.
14. Bainbridge, J. W., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S. S., Thrasher, A. J., Fitzke, F. W., Carter, B. J., Rubin, G. S., Moore, A. T., and Ali, R. R. (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis, N Engl J Med 358, 2231–2239.
15. Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell’Osso, L., Hertle, R., Ma, J. X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., and Bennett, J. (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis, N Engl J Med 358, 2240–2248.
16. Cideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, S. L., Windsor, E. A., Conlon, T. J., Sumaroka, A., Pang, J. J., Roman, A. J., Byrne, B. J., and Jacobson, S. G. (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year, Hum Gene Ther 20, 999–1004.
17. Clark, K. R., Voulgaropoulou, F., and Johnson, P. R. (1996) A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors, Gene Ther 3, 1124–1132.
18. Chadeuf, G., Favre, D., Tessier, J., Provost, N., Nony, P., Kleinschmidt, J., Moullier, P., and Salvetti, A. (2000) Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome, J Gene Med 2, 260–268.
19. Knop, D. R., and Harrell, H. (2007) Bioreactor production of recombinant herpes simplex virus vectors, Biotechnol Prog 23, 715–721.
20. Merten, O. W. (2007) Attention with virus contaminated cell lines, Cytotechnology 55, 1–2.
21. Van Vliet, K., Blouin, V., Agbandje-McKenna, M., and Snyder, R. O. (2006) Proteolytic mapping of the adeno-associated virus capsid, Mol Ther 14, 809–821.
22. Van Vliet, K., Mohiuddin, Y., McClung, S., Blouin, V., Rolling, F., Moullier, P., Agbandje-McKenna, M., and Snyder, R. O. (2009) Adeno-associated virus capsid serotype identification: Analytical methods development and application, J Virol Methods 159, 167–177.
23. Lock, M., McGorray, S., Auricchio, A., Ayuso, E., Beecham, E. J., Blouin-Tavel, V., Bosch, F., Bose, M., Byrne, B. J., Caton, T., Chiorini, J. A., Chtarto, A., Clark, K. R., Conlon, T., Darmon, C., Doria, M., Douar, A., Flotte, T. R., Francis, J. D., Francois, A., Giacca, M., Korn, M. T., Korytov, I., Leon, X., Leuchs, B., Lux, G., Melas, C., Mizukami, H., Moullier, P., Muller, M., Ozawa, K., Philipsberg, T., Poulard, K., Raupp, C., Riviere, C., Roosendaal, S. D., Samulski, R. J., Soltys, S. M., Surosky, R., Tenenbaum, L., Thomas, D. L., van Montfort, B., Veres, G., Wright, J. F., Xu, Y., Zelenaia, O., Zentilin, L., and Snyder, R. O. (2010) Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material, Hum Gene Ther 21, 1273–1285.
24. Zhen, Z., Espinoza, Y., Bleu, T., Sommer, J. M., and Wright, J. F. (2004) Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events, Hum Gene Ther 15, 709–715.
25. Mohiuddin, I., Loiler, S., Zolotukhin, I., Byrne, B. J., Flotte, T. R., and Snyder, R. O. (2005) Herpesvirus-based infectious titering of recombinant adeno-associated viral vectors, Mol Ther 11, 320–326.
26. Snyder, R. O., Xiao, X., and Samulski, R. J. (1996) Production of Recombinant Adeno-Associated Viral Vectors, in Current Protocols in Human Genetics (Dracopoli, N., Haines, J., Krof, B., Moir, D., Morton, C., Seidman, C., Seidman, J., and Smith, D., Eds.), pp 12.11.11-24, John Wiley and Sons, New York.
27. Nony, P., Chadeuf, G., Tessier, J., Moullier, P., and Salvetti, A. (2003) Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles, J Virol 77, 776–781.
28. Gao, G. P., Qu, G., Faust, L. Z., Engdahl, R. K., Xiao, W., Hughes, J. V., Zoltick, P. W., and Wilson, J. M. (1998) High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus (In Process Citation), Hum Gene Ther 9, 2353–2362.
29. Grimm, D., Kern, A., Pawlita, M., Ferrari, F., Samulski, R., and Kleinschmidt, J. (1999) Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2, Gene Ther 6, 1322–1330.
30. Wistuba, A., Kern, A., Weger, S., Grimm, D., and Kleinschmidt, J. A. (1997) Subcellular compartmentalization of adeno-associated virus type 2 assembly, J Virol 71, 1341–1352.
31. Grimm, D., Kay, M. A., and Kleinschmidt, J. A. (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6, Mol Ther 7, 839–850.
32. Sommer, J. J., Smith, P. H., Parthasarathy, S., Isaacs, J., Vijay, S., Kieran, J., Powell, S. K., McClelland, A., and Wright, J. F. (2003) Quantification of adeno-associated virus particles and empty capsids by optical density measurement, Mol Ther 7, 122–128.
33. Clark, K. R., Liu, X., McGrath, J. P., and Johnson, P. R. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, Hum Gene Ther 10, 1031–1039.
34. Drittanti, L., Rivet, C., Manceau, P., Danos, O., and Vega, M. (2000) High throughput production, screening and analysis of adeno-associated viral vectors, Gene Ther 7, 924–929.
35. Veldwijk, M. R., Topaly, J., Laufs, S., Hengge, U. R., Wenz, F., Zeller, W. J., and Fruehauf, S. (2002) Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks, Mol Ther 6, 272–278.
36. Flotte, T. R., Burd, P., and Snyder, R. O. (2002) Utility of a Recombinant Adeno-Associated Viral Vector Reference Standard, BioProcessing 1, 75–77.
37. Moullier, P., and Snyder, R. O. (2008) International efforts for recombinant adeno-associated viral vector reference standards, Mol Ther 16, 1185–1188.